Oct 19, 202656 min
In this episode of "In the Interim…", Scott Berry is joined by Jenny Devenport and Kaspar Rufibach of Merck Group, co-authors of the EFSPI Statistical Methodology Leaders paper "Statistical Methodology Groups in the...
science
In the Interim...
Hosted by Berry · science · EN
About this Podcast:
A podcast on statistical science and clinical trials.Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.
Pitch Analysis
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
34%
Guest openness
Selective
80/100
Required Score
Sign up to generate a grounded pitch for In the Interim....
Signup to Generate a PitchQuestions about In the Interim...
What is In the Interim... about?
A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers.
Who hosts In the Interim...?
In the Interim... is hosted by Berry. The show has published 82 episodes to date.
What has In the Interim... covered recently?
Recent episodes include "Statistical Methodology Groups in the Pharmaceutical Industry" (19 October 2026, 56 minutes), "A Discussion on Virtual Controls" (12 October 2026, 47 minutes), and "Clinical Trial Arenas: Direct Communication to Patients" (28 September 2026, 43 minutes).
How often does In the Interim... publish?
In the Interim... publishes roughly weekly, with episodes averaging 48 minutes across 82 episodes.
How hard is it to get booked on In the Interim...?
Booking probability for In the Interim... is 34%, and the host is rated Selective on guests. In the Interim... requires a Pod Score of 80 or higher. In the Interim...'s contact route on record: verified email.
Who should pitch In the Interim...?
The strongest fits for In the Interim... are Scientific Research & Development. In the Interim... has a science audience.
About the host
Berry hosts In the Interim..., a science podcast with 82 episodes published.
Verified host email: ████████@████.comSign in to unlock →
Recent episodes
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #81
A Discussion on Virtual Controls
Oct 12, 202647 minIn this episode of "In the Interim…", Dr. Scott Berry shares the framework he presented at a CSRC regulatory science hackathon on digital twins and synthetic controls in cardiovascular clinical trials. He separates...
- Sep 28, 202643 min
In this episode of "In the Interim…", Dr. Scott Berry recounts a presentation he gave to the Speak Foundation, a patient organization focused on limb-girdle muscular dystrophy and makes the case for master protocols...
Episode #79
Science Coaching With Alun Bedding
Sep 21, 202645 minIn this episode of "In the Interim…", Dr. Scott Berry talks with Dr. Alun Bedding, a professional certified coach and statistician who spent decades in pharmaceutical statistics, including as global head of statistical...
- Sep 14, 202646 min
In this episode of “In the Interim…,” Dr. Scott Berry talks with Dr. Roger Lewis, Dr. Anna McGlothlin, and Dr. Nick Berry — all co-authors on the CHIPS trial results recently published in JAMA (Spinella et al., August...
View More
Episode #77
NFL Study of CTE: The Issues
Sep 7, 202639 minIn this episode of "In the Interim…", Dr. Scott Berry examines three recent health-research headlines through a statistician's lens: an Adventist Health Study-2 analysis claiming eggs reduce Alzheimer's risk, an Emory...
Episode #76
Talkin' 'bout Sweet Time
Aug 31, 202647 minIn this episode of "In the Interim...", Dr. Scott Berry dissects prevailing concepts of “clinically meaningful difference” in clinical trials focusing on progressive diseases. Through detailed examples from pancreatic...
- Aug 17, 20261h 6m
In this episode of "In the Interim…", Dr. Don Berry provides a detailed account of co-chairing the 1997 NIH consensus development conference on mammography for women in their 40s. His conversation with Dr. Scott Berry...
- Aug 10, 202652 min
In this episode of "In the Interim…", Dr. Scott Berry speaks with Dr. Srinivas Murthy, Dr. Thomas Hills, and Dr. Lindsay Berry about the REMAP-CAP trial results on oseltamivir in critically ill influenza patients. The...
Episode #73
ICECAP: The Results
Aug 5, 202655 minIn this episode of "In the Interim…", Dr. Scott Berry leads a comprehensive discussion of the ICECAP trial results with four Principal Investigators: Dr. Will Meurer (Professor, Emergency Medicine and Neurology...
Episode #70
A Visit With Tim Berry
Jul 20, 202644 minIn this episode of "In the Interim…," Dr. Scott Berry interviews Tim Berry, co-founder of Blend360, detailing a career that demonstrates the practical application of statistical and analytical methods within large-scale...
Episode #69
Fairness in Soccer and Clinical Trials
Jul 13, 202635 minIn this episode of "In the Interim...", Dr. Scott Berry investigates the practical meaning of fairness by connecting a controversial World Cup soccer ruling to foundational questions in clinical trial statistics. Scott...
Episode #68
Bias in Stopping Trials Early
Jul 6, 202639 minOn the latest episode of "In the Interim...", Dr. Scott Berry and Dr. Kert Viele deliver a focused, technical analysis of statistical bias when stopping trials early. This episode clarifies the definition of bias...
Episode #67
A Statistician Reads JAMA: A Futile Issue
Jun 22, 202646 minS0<p>On the latest episode of "In the Interim…", Dr. Scott Berry provides an empirical examination of two recent JAMA trials: TRACK (low-dose rivaroxaban in advanced kidney disease) and VICTORY (IV vitamin C in severe...
- Jun 15, 202647 minS0
<p>In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine response-adaptive randomization (RAR) in clinical trials, dissecting its statistical rationale, common criticisms, and implementation...
Episode #65
REMAP-CAP: The Origin
Jun 8, 202653 minS0<p>In this episode of "In the Interim…", Dr. Scott Berry explores the origins of REMAP-CAP with Prof. Steve Webb, former chair of the REMAP-CAP International Trial Steering Committee. This episode examines how pandemic...
Episode #64
Fighting Time in Adaptive Trials
Jun 1, 202656 minS0<p>In this episode of "In the Interim…", Dr. Scott Berry explores the challenge of protracted endpoint timelines in adaptive clinical trials and the statistical strategies used to increase the rate of actionable...
Episode #63
ICECAP: The Adaptive Design
May 25, 202651 minS0<p>In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Will Meurer, professor of Emergency Medicine and Neurology at the University of Michigan, for an in-depth discussion of the ICECAP trial’s...
Episode #62
Multi-Platform RCT
May 18, 202633 minS0<p>In this episode of "In the Interim…", Dr. Scott Berry details the design, execution, and results of the multi-platform randomized clinical trial (mpRCT) pioneered during the COVID-19 pandemic. He describes how...
- May 11, 202651 minS0
<p>In this episode of "In the Interim…", Dr. Scott Berry examines the analytical challenges of comparing performance across eras in both sports and clinical research. Drawing from statistically robust family debates and...
Recent guests
Recent guests on In the Interim.... Study who booked and why before you pitch.
Best industries to pitch In the Interim... for
PitchCentric classifies In the Interim... under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Similar Podcasts
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
ASA Biopharm's Podcast
29~412 listeners83% similar
Baseline Observations
15~208 listeners82% similar
Casual Inference
26~378 listeners82% similar
JAMAevidence JAMA Guide to Statistics and Methods
23~334 listeners82% similar
Practical Significance
15~208 listeners81% similar
Clinical Data Talks
19~268 listeners81% similar
Podcasts like In the Interim...
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ